{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:20:31Z","timestamp":1778628031093,"version":"3.51.4"},"reference-count":9,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100014364","name":"National Children's Research Centre","doi-asserted-by":"publisher","award":["J\/15\/1"],"award-info":[{"award-number":["J\/15\/1"]}],"id":[{"id":"10.13039\/100014364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPGN rep."],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric ulcerative colitis (UC) is typically more extensive and severe at diagnosis compared with adult disease. Tofacitinib, a Janus kinase inhibitor, has been used since 2018 to induce and maintain remission in UC. There are limited pediatric data regarding its use, either as a monotherapy or in combination with other treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the real\u2010world experience and outcomes of tofacitinib therapy in the Irish national cohort with pediatric UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study of tofacitinib outcomes was undertaken at Ireland's single national center for pediatric inflammatory bowel disease. All patients commenced on tofacitinib since its availability in 2019 were included. Baseline and follow\u2010up clinical characteristics, phenotype, Pediatric Ulcerative Colitis Activity Index (PUCAI) scores, and treatments before and after tofacitinib commenced were recorded. The primary outcome was remission by 8 weeks, with other clinical outcomes being recorded to maximal available follow\u2010up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between November 1, 2019 and June 30, 2022, 15 children (M:F 1:2) were prescribed tofacitinib, 5 as monotherapy. Thirteen had baseline pancolitis at diagnosis and all patients had prior infliximab exposure. The mean time from diagnosis to starting tofacitinib was 381\u00a0days (\u00b1SD 265). Dual therapy included 5 with infliximab, 4 with vedolizumab, and 1 with adalimumab. The average length of treatment on tofacitinib was 232\u00a0days (\u00b1SD 170) with 2 patients transitioning to adult services while in remission on tofacitinib therapy. The mean PUCAI score was 48.7 (\u00b1SD 14.1) pre\u2010tofacitinib, 16.7 (\u00b1SD 15.6) at week 8, and 22.5 (\u00b1SD 29.6) by week 16, with a significant reduction in PUCAI by week 16 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0004). Eight patients (3 monotherapy) achieved clinical remission, with 4 of the 5 dual therapy patients on infliximab. There were no significant outcome differences between those on mono\u2010 or dual therapy. Three patients with combined vedolizumab therapy did not achieve remission, 2 of whom required colectomy by week 24. There were no malignancies, 1 patient developed shingles and another developed herpangina post\u2010tofacitinib. Failure to achieve clinical remission by week 16 was seen in all children who progressed to colectomy (n = 4).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combining tofacitinib with other biologics is effective in select children with refractory UC. Early responders were more likely to achieve a sustained response at week 16. Failure to achieve remission by week 16 of tofacitinib therapy was strongly associated with progression to colectomy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/pg9.0000000000000332","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T14:03:03Z","timestamp":1687788183000},"source":"Crossref","is-referenced-by-count":13,"title":["Outcomes of Tofacitinib Use in an Irish Pediatric Cohort"],"prefix":"10.1002","volume":"4","author":[{"given":"Niamh","family":"Ryan","sequence":"first","affiliation":[{"name":"National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Cooper","sequence":"additional","affiliation":[{"name":"National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"},{"name":"DOCHAS Study National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dominik","sequence":"additional","affiliation":[{"name":"National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"},{"name":"DOCHAS Study National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoana","family":"Quinn","sequence":"additional","affiliation":[{"name":"National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"Broderick","sequence":"additional","affiliation":[{"name":"National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"},{"name":"School of Medicine University College Dublin Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billy","family":"Bourke","sequence":"additional","affiliation":[{"name":"National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"},{"name":"School of Medicine University College Dublin Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9amus","family":"Hussey","sequence":"additional","affiliation":[{"name":"National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"},{"name":"DOCHAS Study National Centre for Pediatric Gastroenterology Children's Health Ireland Dublin Ireland"},{"name":"School of Medicine University College Dublin Dublin Ireland"},{"name":"Department of Paediatrics Royal College of Surgeons of Ireland Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050730"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.029"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30252-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003190"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa277"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003616"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.934460"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab278"}],"container-title":["JPGN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/PG9.0000000000000332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1097\/PG9.0000000000000332","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/PG9.0000000000000332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:30:27Z","timestamp":1778149827000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/PG9.0000000000000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1097\/PG9.0000000000000332"],"URL":"https:\/\/doi.org\/10.1097\/pg9.0000000000000332","archive":["Portico"],"relation":{},"ISSN":["2691-171X","2691-171X"],"issn-type":[{"value":"2691-171X","type":"print"},{"value":"2691-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"article-number":"e332"}}